Fzata, Inc. has been awarded a $7 million grant from the National Institutes of Health (NIH) to develop a groundbreaking oral treatment for chronic visceral pain associated with inflammatory bowel syndrome (IBS). The grant will fund pre-clinical and Phase 1 clinical trials for FZ006, a novel drug candidate based on Fzata’s BioPYMTM platform technology.